Rebiotix
Rebiotix is a clinical-stage biotechnology company developing standardized microbiome therapeutics based on fecal microbiota transplantation to treat recurrent C. difficile infections, operating as a wholly-owned subsidiary of Ferring Pharmaceuticals since 2018.
- Company typePrivate
- Founded2011
- HeadquartersRockville, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Rebiotix does
Rebiotix is a development-stage biotechnology company founded in 2011 that develops human microbiome therapeutics for gastrointestinal diseases, with a primary focus on treating recurrent Clostridioides difficile infection (CDI). The company's core technology is fecal microbiota transplantation (FMT), delivered through a pipeline of standardized, manufactured microbiome-based therapeutic candidates designed to restore healthy gut microbiota. The company is differentiated from traditional FMT approaches by its emphasis on pharmaceutical-grade manufacturing consistency, scalability, and regulatory-grade product development. FMT-based therapies account for approximately 79% of the microbiome therapeutics market in 2025, underscoring the commercial relevance of Rebiotix's chosen modality.
Rebiotix was acquired by Ferring Pharmaceuticals in 2018 and operates as a wholly-owned subsidiary, benefiting from Ferring's capital base, manufacturing expertise, and global pharmaceutical distribution capabilities. The company is based in Roseville, MN (with firmographics listing Rockville as well), with operations including a stool donor screening and sample collection facility supporting microbiome research. The GiveACrapMN donor program recruits and screens healthy donors, compensating them $50 per COVID-19 test and $30 per qualifying donation, building the raw material pipeline for therapeutic development. Rebiotix is led by co-founder Lee Jones (President & CEO), with Erwin Kelen as co-founder.
The business model follows the pharmaceutical pathway: clinical validation through trials, regulatory milestones including FDA designations, and eventual prescription-based product distribution through hospital and specialty pharmacies upon approval. The company is pre-revenue with no commercial products on the market, generating no disclosed revenue. Future revenue will derive from pharmaceutical product sales contingent on regulatory approval. Go-to-market efforts are channeled through scientific publications, clinical trial announcements, medical conferences, and healthcare industry partnerships rather than direct consumer marketing. In August 2024, Rebiotix expanded its pipeline and manufacturing capabilities under Ferring's ownership, signaling continued investment toward potential commercialization.
Rebiotix firmographics
Firmographics- Name
- Rebiotix
- Legal name
- Rebiotix Inc.
- Website
- https://rebiotix.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Rebiotix is a clinical-stage biotechnology company developing standardized microbiome therapeutics based on fecal microbiota transplantation to treat recurrent C. difficile infections, operating as a wholly-owned subsidiary of Ferring Pharmaceuticals since 2018.
- Ownership category
- akta.pro rank
Rebiotix industry classification
Industry- Product category
- Microbiome Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Fecal Microbiota Transplantation (FMT) & Microbiota Restoration Products (HLAAAFAE)
- akta.pro secondary industries
- Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK)
Keywords
Where Rebiotix is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Rebiotix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Rebiotix is developing microbiome therapeutic products that will generate revenue through pharmaceutical product sales upon regulatory approval. The company is expanding manufacturing capabilities to support eventual commercial production.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Rebiotix product offering
Product offeringCore offering
Rebiotix is a clinical-stage biotechnology company developing standardized, manufactured microbiome therapeutics based on fecal microbiota transplantation (FMT). Its lead focus is the treatment and prevention of recurrent Clostridioides difficile infection, with a broader pipeline aimed at other microbiome-related gastrointestinal and systemic diseases. The company supports development with an in-house stool donor screening and collection program.
Product overview
No product or service information available for Rebiotix in the provided source data.
Differentiator
Problem solved
Functional benefit
Products and services
- Microbiome Therapeutic Pipeline (FMT-based candidates for recurrent CDI) A clinical-stage pipeline of standardized, manufactured fecal microbiota transplantation (FMT)-based therapeutic candidates intended for the treatment and prevention of recurrent Clostridioides difficile infection and other microbiome-related diseases, to be prescribed by healthcare providers upon regulatory approval.
- GiveACrapMN Stool Donor Program A stool donor screening and collection program supporting Rebiotix's microbiome therapeutics development for C. difficile research. Located at 2660 Patton Road, Roseville, MN, the program recruits, screens, and compensates donors to supply material for FMT-based therapeutic development.
Quantifiable outcome
- FMT achieves high clinical success rates in treating recurrent CDI, with the fecal microbiota transplantation segment accounting for approximately 79% of the microbiome therapeutics market in 2025
Companies that use Rebiotix
Customer profileSegments1 record
Ideal customer profiles1 record
Rebiotix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Rebiotix partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights3 records
Rebiotix competitors and assessment
Company assessmentDirect peers
- Seres Therapeutics: Seres Therapeutics developed Vowst, the first orally administered microbiome therapeutic approved by the FDA for prevention of recurrent CDI in 2023. It is the most direct competitor to Rebiotix/Ferring's Rebyota, targeting the same recurrent CDI patient population with a defined-consortium microbiome approach.
- MaaT Pharma: MaaT Pharma is a European clinical-stage microbiome therapeutics company developing standardized, pooled-donor FMT-like products (MaaT013, MaaT033) for GI diseases including CDI and graft-versus-host disease. It is a direct peer operating the same standardized FMT manufacturing model as Rebiotix.
- Vedanta Biosciences: Vedanta Biosciences is developing defined bacterial consortium microbiome therapeutics, including programs in CDI and other GI indications. It is a clinical-stage direct peer pursuing a more synthetic, defined-strain approach to microbiome therapeutics in overlapping indications.
Emerging players
- Assembly Biosciences: Assembly Biosciences has pivoted portions of its pipeline into microbiome-based approaches for serious diseases. It is an emerging clinical-stage player with overlap in microbiome therapeutic modalities targeting similar GI and immunological indications.
- Siolta Therapeutics: Siolta Therapeutics is a clinical-stage company developing defined-consortium live biotherapeutic products for inflammatory diseases including ulcerative colitis and asthma. It is an emerging peer in standardized microbiome therapeutics targeting overlapping inflammatory indications.
- Second Genome: Second Genome is a clinical-stage company using microbiome-based drug discovery to identify novel therapeutics for serious diseases. It is an emerging peer applying microbiome science to drug development in overlapping GI and metabolic indications.
- 4D pharma: 4D pharma was a UK-based clinical-stage microbiome therapeutics company developing live biotherapeutics for cancer and GI disease. It is an emerging peer in the broader live-biotherapeutic category overlapping Rebiotix's therapeutic areas, though it has undergone significant restructuring.
- Finch Therapeutics: Finch Therapeutics developed Finch 301 (CP101), an FMT-based oral microbiome therapeutic for recurrent CDI, before restructuring. It remains a relevant emerging peer in FMT-based microbiome therapeutics with comparable technology and target indication to Rebiotix.
- Evelo Biosciences: Evelo Biosciences is developing oral, single-strain microbiome therapeutics for inflammatory diseases. It represents an emerging-player approach using defined microbial strains rather than full FMT, competing in adjacent indications to Rebiotix's pipeline expansion plans.
Broad incumbents
- Ferring Pharmaceuticals: Ferring Pharmaceuticals is Rebiotix's parent company and a global specialty pharma with deep GI and reproductive health franchises. It is included as a peer because it owns and commercializes Rebyota (developed by Rebiotix), making it the commercial channel and strategic owner of Rebiotix's lead asset.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Rebiotix social profiles
Digital presenceRebiotix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rebiotix leadership team
Management profileNumber of profiles
Profiles2 records
Rebiotix funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rebiotix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rebiotix
What does Rebiotix do?
Rebiotix is a clinical-stage biotechnology company developing standardized, manufactured microbiome therapeutics based on fecal microbiota transplantation (FMT). Its lead focus is the treatment and prevention of recurrent Clostridioides difficile infection, with a broader pipeline aimed at other microbiome-related gastrointestinal and systemic diseases. The company supports development with an in-house stool donor screening and collection program.
Is Rebiotix a public or private company?
Rebiotix is a private company. It is classified as corporate owned and is currently operating.
When was Rebiotix founded?
Rebiotix was founded in 2011. It employs 11 to 50 people.
Where is Rebiotix based?
Rebiotix is headquartered in Rockville, United States, in the North America region.
How does Rebiotix make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Rebiotix's main competitors?
Direct peers on record are Seres Therapeutics, MaaT Pharma and Vedanta Biosciences. Emerging players are Assembly Biosciences, Siolta Therapeutics, Second Genome, 4D pharma, Finch Therapeutics and Evelo Biosciences. Ferring Pharmaceuticals is listed as a broad incumbent.
Does Rebiotix have an API?
No public API is recorded for Rebiotix.
What industry is Rebiotix in?
Rebiotix's product category is Microbiome Therapeutics. Its primary akta.pro industry code is HLAAAFAE, Fecal Microbiota Transplantation (FMT) & Microbiota Restoration Products, with a secondary code of HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery). Its NAICS code is 325414 and its SIC code is 2836.